# SYNTRIX BIOSYSTEMS, INC.: A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | SYNTRIX BIOSYSTEMS, INC. |
| Location | AUBURN, WA |
| Project | A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients |
| Project number | 5R44CA291622-03 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $740,293 |
| Awarded | 2026-09-17 |
| Project period | 2025-05-01 to 2028-04-30 |
| UEI | L5Z8K6ZE8LY4 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11324659). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.